Janssen has played a leading role in the advancement of both transformational treatments and understanding of the underlying science of psoriasis for the past decade. Building from successful tumor necrosis factor (TNF)-alpha therapy, we demonstrated the essential roles for inhibiting interleukin (IL)-12 and IL-23 in the pathogenesis of psoriasis, establishing a new, differentiated treatment. And we continue to evaluate targeted therapies, focusing in on new mechanisms of action around IL-23 inhibition and alternative targets with oral therapeutics.

We will continue to strive to meet the needs of the total continuum of patients by utilizing innovative technology and our disease expertise to provide integrated therapies for the dermatology community. Our scientists are already at the forefront of molecularly defining psoriasis at the local tissue level using gene expression analysis, as well as systemically using flow cytometry and protein profiling.

Our ultimate goal is to provide maximum levels of skin clearance to treat the full range of patients with psoriasis. As we continue to access emerging science, we look to identify opportunities for early prevention, interception and long-term remission of this chronic, sometimes debilitating, disease.